![Doug Treco Treco](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Doug Treco Treco
Directeur/Membre du Conseil chez
CRISPR THERAPEUTICS AG
Fortune : 1 M $ au 31/05/2026
Profil
Douglas A. Treco was the founder of Transkaryotic Therapies, Inc., founded in 1988, where the title held was Senior Vice President-Research & Development from 1988 to 2005.
Dr. Treco was the founder of RA Pharmaceuticals, Inc., founded in 2008, where the title held was President & Chief Executive Officer in 2020.
Current jobs include Lead Independent Director at CRISPR Therapeutics AG since 2021, Scientific Advisor at LSV Capital Management LLC, and Special Advisor at 3CC Management LLC.
Former jobs include Chief Executive Officer & Director at Alchemab Therapeutics Ltd. from 2021 to 2022, Chairman & Chief Executive Officer at Inozyme Pharma, Inc. from 2023 to 2025, Director at Xcellerex, Inc., and Entrepreneur-in-Residence at Morgenthaler Management Corp.
from 2008 to 2014.
Education history includes a doctorate from Stony Brook University conferred in 1984 and an undergraduate degree from the University of Delaware conferred in 1979.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CRISPR THERAPEUTICS AG 0,02 % | 05/06/2026 | 22 000 ( 0,02 % ) | 1 M $ | 31/05/2026 |
Postes actifs de Doug Treco Treco
| Sociétés | Poste | Début |
|---|---|---|
| CRISPR THERAPEUTICS AG | Directeur/Membre du Conseil | 11/06/2020 |
LSV CAPITAL MANAGEMENT LLC
 LSV CAPITAL MANAGEMENT LLC Investment ManagersFinance LSV Capital Management invests in companies located across the globe. The firm targets companies operating in the fields of healthcare, biotech, and medtech sectors. It provides financing for seed, early, and later stage capital requirements. | Consultant / Advisor | - |
3CC Management LLC
 3CC Management LLC Investment ManagersFinance Third Culture Capital invests in companies located in the United States. The firm focuses on the healthcare sector. It provides financing for seed and early stage capital requirements with an investment size ranging between USD 0.25 - 1 million. It acts as a lead investor. | Consultant / Advisor | - |
Anciens postes connus de Doug Treco Treco
| Sociétés | Poste | Fin |
|---|---|---|
| INOZYME PHARMA, INC. | Directeur Général | 01/07/2025 |
Alchemab Therapeutics Ltd.
 Alchemab Therapeutics Ltd. BiotechnologyHealth Technology Engages in developing of antibodies | Directeur Général | 26/05/2022 |
| RA PHARMACEUTICALS, INC. | Fondateur | 01/07/2020 |
Morgenthaler Management Corp.
 Morgenthaler Management Corp. Investment ManagersFinance Morgenthaler invests in companies located in the United State with an EBITDA of USD 8 - 40 million. The firm focuses on companies operating in the fields of information technology and life sciences sectors. It provides financing for early and later stage capital requirements. | Private Equity Investor | 31/01/2014 |
Transkaryotic Therapies, Inc.
 Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Develops and markets biopharmaceutical products | Fondateur | 01/01/2005 |
Formation de Doug Treco Treco
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
80
Relations au 1er degré
11
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 11 |
|---|---|
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Develops and markets biopharmaceutical products | Commercial Services |
Xcellerex, Inc.
 Xcellerex, Inc. Pharmaceuticals: MajorHealth Technology Offers contract services for bioprocess development and manufacturing | Health Technology |
Ra Pharmaceuticals, Inc.
 Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of glomerulonephritis, kidney disease and cardiovascular disease | Health Technology |
Stony Brook University
 Stony Brook University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Delaware
 University of Delaware Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Morgenthaler Management Corp.
Morgenthaler Management Corp. Investment ManagersFinance Morgenthaler invests in companies located in the United State with an EBITDA of USD 8 - 40 million. The firm focuses on companies operating in the fields of information technology and life sciences sectors. It provides financing for early and later stage capital requirements. | Finance |
LSV CAPITAL MANAGEMENT LLC
LSV CAPITAL MANAGEMENT LLC Investment ManagersFinance LSV Capital Management invests in companies located across the globe. The firm targets companies operating in the fields of healthcare, biotech, and medtech sectors. It provides financing for seed, early, and later stage capital requirements. | Finance |
CRISPR Therapeutics AG
 CRISPR Therapeutics AG BiotechnologyHealth Technology Develops gene-based medicines | Health Technology |
Inozyme Pharma, Inc.
 Inozyme Pharma, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines | Health Technology |
Alchemab Therapeutics Ltd.
Alchemab Therapeutics Ltd. BiotechnologyHealth Technology Engages in developing of antibodies | Health Technology |
3CC Management LLC
3CC Management LLC Investment ManagersFinance Third Culture Capital invests in companies located in the United States. The firm focuses on the healthcare sector. It provides financing for seed and early stage capital requirements with an investment size ranging between USD 0.25 - 1 million. It acts as a lead investor. | Finance |
Choisissez Zonebourse 
